One To Watch
Abivax
Company Overview
A French clinical-stage biotechnology company developing oral small-molecule immunomodulators for chronic inflammatory diseases, led by its first-in-class miR-124 enhancer obefazimod in ulcerative colitis. Abivax focuses on harnessing the body's natural regulatory mechanisms to modulate immune responses without broadly suppressing immunity. The company has advanced its lead asset through pivotal Phase III trials and is now positioning itself for potential commercialization in inflammatory bowel disease.
Headquarters and Global Presence
Abivax is headquartered in Paris, France, and is listed on both Euronext Paris and the Nasdaq Global Market under the ticker ABVX. The company has expanded its operational footprint to support US commercialization activities following its Nasdaq listing in 2024.
Founding and History
Abivax was founded as a French biotech with roots in antiviral and immunology research, initially attracting attention for HIV-related work before pivoting its strategic focus to chronic inflammatory diseases. The company completed an oversubscribed 49.2 million-euro crossover financing in late 2022, followed by a 130 million-euro ($139 million) round in early 2023. Marc de Garidel was appointed CEO and interim board chairman in May 2023, bringing renewed commercial focus. Abivax completed a Nasdaq IPO in June 2024, raising approximately $236 million and accessing the US capital markets for the first time.
Therapy Areas and Focus
Abivax is concentrated on moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease affecting millions of patients globally with significant unmet need for well-tolerated oral therapies. The company's rationale centers on the limitations of existing biologics — including immunogenicity, injection burden, and tolerability issues — and the competitive advantage of a once-daily oral agent with a differentiated mechanism. Abivax has also explored obefazimod in rheumatoid arthritis, broadening the potential of its core platform beyond gastroenterology.
Technology Platforms and Modalities
Obefazimod works by enhancing the expression of microRNA-124 (miR-124), a naturally occurring regulatory RNA that dampens pro-inflammatory cytokine production. This mechanism is distinct from existing JAK inhibitors and biologics targeting TNF, IL-12/23, or integrin pathways, operating upstream in the inflammatory cascade. The approach is designed to restore immune homeostasis selectively, potentially offering a more targeted and durable anti-inflammatory effect without the broad immunosuppression associated with current standard-of-care options. The once-daily oral formulation is a key commercial differentiator in a market still dominated by injectable biologics.
Key Pipeline and Programs
Obefazimod (ABX464) is Abivax's lead asset — a first-in-class, once-daily oral miR-124 enhancer evaluated in adults with moderately to severely active ulcerative colitis. In July 2025, the company announced positive top-line results from two pivotal Phase III induction trials, ABTECT-1 (Study 105) and ABTECT-2 (Study 106), triggering an extraordinary 389% single-day share price surge. Prior to these pivotal data, an open-label maintenance study reported positive interim efficacy and safety results in October 2024, and a Phase IIb trial had already demonstrated encouraging two-year durability data. The Phase IIb program enrolled 254 patients with moderate-to-severe UC and demonstrated the safety and efficacy profile that underpinned the Phase III design. Abivax has also investigated obefazimod in rheumatoid arthritis, though ulcerative colitis remains the primary regulatory and commercial focus as the company advances toward a potential NDA/BLA submission.
Recent Developments
The pivotal Phase III ABTECT-1 and ABTECT-2 induction trials reported positive top-line results in July 2025, representing the most significant clinical milestone in Abivax's history. A subsequent public offering completed in the same week raised $747.5 million, underscoring strong investor conviction in the obefazimod data package. In March 2026, Abivax announced the appointment of three key executives to support commercialization readiness. In May 2026, the company repurchased outstanding royalty certificates tied to obefazimod and raised an additional $45 million, streamlining its capital structure ahead of a potential regulatory filing.
Key Personnel
Marc de Garidel serves as Chief Executive Officer. He was appointed in May 2023 and has driven Abivax's pivot to a commercially oriented, publicly traded entity listed on both Euronext and Nasdaq. Michael Ferguson serves as Chief Commercial Officer, bringing prior experience at Arena Pharmaceuticals and Shire/Takeda, giving him a strong background in gastrointestinal and rare disease commercialization. Jean-Marc Steens has served as Chief Medical Officer, overseeing the design and execution of the pivotal ABTECT Phase III program.
Strategic Partnerships
Abivax has operated largely as an independent developer without a major pharma co-development partner disclosed to date, a strategic posture that preserves upside but increases capital dependency. The company's successive oversubscribed financings — including the $747.5 million post-Phase III offering — reflect deep backing from US and European biotech specialist investors. Abivax's repurchase of royalty certificates in May 2026 further consolidates economic ownership of obefazimod ahead of any future licensing or commercial discussions.
FAQ Section
Abivax is targeting the large population of UC patients who fail or are intolerant to existing biologics, positioning obefazimod as a first-in-class oral option with a fundamentally different mechanism from JAK inhibitors and anti-TNF agents. The once-daily oral formulation addresses a key patient preference over injectables, and positive Phase III induction data from both ABTECT-1 and ABTECT-2 give the company a credible regulatory pathway. The July 2025 data readout and subsequent $747.5 million capital raise signal commercial-stage ambitions.
MicroRNA-124 (miR-124) is an endogenous regulatory RNA that acts as a natural brake on inflammatory signaling, suppressing the production of multiple pro-inflammatory cytokines simultaneously. By enhancing miR-124 expression, obefazimod works upstream of the cytokine cascade rather than blocking a single target, theoretically offering broader and more durable anti-inflammatory control. This pleiotropic mechanism may explain the durability signals observed in Abivax's Phase IIb two-year follow-up data.
Approved JAK inhibitors broadly suppress cytokine signaling and carry regulatory black box warnings for cardiovascular risk, malignancy, and thrombosis, limiting their use to patients who have failed biologics. Obefazimod's miR-124 enhancement mechanism is selective and endogenous rather than enzymatic inhibition, which Abivax argues should translate into a cleaner safety profile. Phase IIb and the subsequent open-label maintenance data have not flagged the safety signals associated with JAK inhibitors, a potential labeling advantage if confirmed in Phase III submission packages.
Both ABTECT-1 (Study 105) and ABTECT-2 (Study 106) met their primary endpoints in 8-week induction in adults with moderately to severely active UC, driving a 389% single-session share price rally in July 2025. These results form the core induction dataset for a regulatory filing; Abivax will also require maintenance trial data to support full approval in most major markets. The company's appointment of commercial executives and its capital structure cleanup in early 2026 suggest a regulatory submission is being actively prepared.
Abivax has investigated obefazimod in rheumatoid arthritis, leveraging the same miR-124 enhancement mechanism in a high-prevalence systemic inflammatory condition. The company's earlier history also includes HIV research, where modulation of host immune regulatory pathways was the original scientific rationale for the molecule. UC remains the lead regulatory focus, but the platform's upstream immune-modulatory mechanism offers a scientific basis for expansion into other chronic inflammatory diseases if the UC program succeeds.
Abivax is a late-stage clinical company with positive Phase III induction data in hand and a commercialization team being assembled ahead of an anticipated regulatory filing. The company listed on Nasdaq in June 2024 raising $236 million, completed a $747.5 million public offering following its Phase III results in July 2025, and raised an additional $45 million in May 2026 after buying back royalty certificates. This capital base positions Abivax to self-fund through regulatory submission and, potentially, early commercial launch without requiring a partnership.
Abivax is at a pivotal inflection point between Phase III data and regulatory submission. Key watchpoints include:
Latest Abivax News
Today's issue
| Headless Content Management with Blaze